Silo Pharma, Inc.
For the period ended Dec 31, 2025. Filed Mar 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 27, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| SILO PHARMA, INC. | ||
| Date: March 27, 2026 | By: | /s/ Eric Weisblum |
|---|---|---|
| Eric Weisblum | ||
| Chairman, Chief Executive Officer | ||
| (Principal Executive Officer) | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Eric Weisblum | Chairman, Chief Executive Officer, | March 27, 2026 |
| Eric Weisblum | President, and Director (Principal Executive Officer) | |
| /s/ Daniel Ryweck | Chief Financial Officer, | March 27, 2026 |
| Daniel Ryweck | (Principal Accounting and Financial Officer) | |
| /s/ Wayne D. Linsley | Director | March 27, 2026 |
| Wayne D. Linsley | ||
| /s/ Dr. Kevin Muñoz | Director | March 27, 2026 |
| Dr. Kevin Muñoz | ||
| /s/ Jeff Pavell | Director | March 27, 2026 |
| Jeff Pavell | ||
-88-
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | |
| Report of Independent Registered Public Accounting Firm (Firm ID No. 106) | F-2 |
|---|---|
| Consolidated Financial Statements: | |
| Consolidated Balance Sheets as of December 31, 2025 and 2024 | F-3 |
| Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2025 and 2024 | F-4 |
| Consolidated Statements of Changes in Stockholders’ Equity for the Years Ended December 31, 2025 and 2024 | F-5 |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2025 and 2024 | F-6 |
| Notes to Consolidated Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.